CytoMed Therapeutics Limited GDTC 深 沪
等待开盘 10-09 09:30:00 美东时间
2.17
+0.010
+0.46%
华盛通- 最 高2.4393
- 今 开2.16
- 成交量 3.75万股
- 最 低 2.15
- 昨 收 2.16
- 总市值 2546.21万
- 52周最高 4.0499
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.65
- 委 比 98.02%
- 总股本 1173.37万
- 历史最高 9.25
- 量 比 1.02
- 振 幅 13.39%
- 历史最低 1.20
- 每 手 1
- 风险率 0.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia
CytoMed Therapeutics, a Singapore-based biopharmaceutical company, announced the publication of a preclinical study in collaboration with MD Anderson Cancer Center, highlighting the potential of its allogeneic γδ T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML). The study suggests promising results for further clinical development, with plans to advance the therapy into clinical trials in Southeast Asia. CytoMed, spun off from A...
10-02 11:00
CytoMed Therapeutics Reports Increased Revenue Amidst Financial Challenges
The latest announcement is out from CytoMed Therapeutics Limited ( ($GDTC) ). O...
09-30 19:29
Grayscale® Near Trust Now Trading on OTCQB® Market
Grayscale® Near Trust (GSNR) begins trading on OTCQB, enabling wider access to the NEAR blockchain platform tailored for AI applications. Near's "intents" simplify cross-chain transactions, enhancing mainstream adoption. Grayscale highlights its role in advancing digital asset investing through institutional-grade products, reflecting its commitment to on-chain innovation.
09-26 13:00
CytoMed Expands Clinical-Scale NK Cells From Decade-Old Cord Blood; Forms New Cord Blood-Derived Biotech Under LongevityBank To Drive Growth And Revenue
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived
08-28 21:07
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition
CytoMed Therapeutics has successfully expanded clinical-scale NK cells from cryopreserved cord blood units, enabling the creation of a new business platform. The company is reorganizing to establish LongevityBank, focusing on autologous therapies, while CytoMed continues developing allogeneic therapies with ongoing clinical trials. The acquisition of a licensed cord blood bank in Malaysia provides access to valuable cord blood for therapeutic dev...
08-28 13:00
CytoMed Therapeutics plans to raise ~$4.3M via ATM offering
Clinical-stage biopharmaceutical company CytoMed Therapeutics (NASDAQ:GDTC) entered into an at-the-market sales agreement with R.F. Lafferty & Co., as the sales agent. The company may offer and sell...
08-19 14:06
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
CytoMed Therapeutics entered into an At-the-Market Sales Agreement with R.F. Lafferty & Co., Inc., allowing the company to sell up to $4.3 million worth of ordinary shares. Proceeds will be used for general corporate purposes, including business diversification, development initiatives, and potential acquisitions or strategic investments. The company has seen 2,500 new customer sign-ups at its newly acquired cord blood bank since August 2024.
08-19 01:00
CytoMed Therapeutics Advances ANGELICA Trial to Dose Level 2
An update from CytoMed Therapeutics Limited ( ($GDTC) ) is now available. On Ju...
07-21 22:27
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies
Singapore-based biopharmaceutical company CytoMed Therapeutics Limited has successfully completed dose level 1 of its Phase I ANGELICA Trial, a first-in-human study evaluating allogeneic gamma delta T cells (CTM-N2D) for treating advanced cancers. The trial involves four late-stage cancer patients, with dose level 2 set to begin in the third quarter of 2025. Unlike traditional CAR-T therapies, which use a patient’s own cells, CTM-N2D uses donor-d...
07-21 14:01
CytoMed Therapeutics Issues Shares to Executives as Compensation
An announcement from CytoMed Therapeutics Limited ( ($GDTC) ) is now available....
07-04 04:28
